Lumos Pharma (LUMO)
(Delayed Data from NSDQ)
$3.93 USD
+0.01 (0.26%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $3.90 -0.03 (-0.76%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Income Statements
Fiscal Year end for Lumos Pharma, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 2 | 2 | 0 | 0 | 1 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 2 | 2 | 0 | 0 | 1 |
Selling & Adminstrative & Depr. & Amort Expenses | 39 | 34 | 32 | 26 | 46 |
Income After Depreciation & Amortization | -37 | -32 | -31 | -26 | -45 |
Non-Operating Income | 3 | 1 | 0 | 7 | 2 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -34 | -31 | -31 | -20 | -43 |
Income Taxes | 0 | 0 | -1 | -14 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -34 | -31 | -30 | -6 | -43 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -34 | -31 | -30 | -6 | -43 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -37 | -32 | -31 | -26 | -44 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 1 | 1 |
Income After Depreciation & Amortization | -37 | -32 | -31 | -26 | -45 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 8.15 | 8.37 | 8.34 | 6.78 | 4.14 |
Diluted EPS Before Non-Recurring Items | -4.18 | -3.71 | -3.65 | -0.93 | -9.27 |
Diluted Net EPS (GAAP) | -4.18 | -3.71 | -3.65 | -0.93 | -10.35 |
Fiscal Year end for Lumos Pharma, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.49 | 0.17 | 0.83 | 0.01 | 0.53 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.49 | 0.17 | 0.83 | 0.01 | 0.53 |
SG&A, R&D, and Dept/Amort Expenses | 8.31 | 11.03 | 10.83 | 8.94 | 10.17 |
Income After SG&A, R&D, and Dept/Amort Expenses | -7.82 | -10.86 | -10.00 | -8.93 | -9.64 |
Non-Operating Income | 0.27 | 0.42 | 0.55 | 0.63 | 0.68 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -7.55 | -10.44 | -9.46 | -8.30 | -8.96 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | -0.03 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -7.55 | -10.44 | -9.46 | -8.30 | -8.93 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -7.55 | -10.44 | -9.46 | -8.30 | -8.93 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 8.11 | 8.11 | 8.08 | 7.98 | 8.17 |
Diluted EPS Before Non-Recurring Items | -0.93 | -1.29 | -1.17 | -1.04 | -1.09 |
Diluted Net EPS (GAAP) | -0.93 | -1.29 | -1.16 | -1.04 | -1.09 |